- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00658905
Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants
October 31, 2014 updated by: Swedish Orphan Biovitrum
A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Infant Formula Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age
The purpose of this study is to evaluate the efficacy in preterm infants following treatment with BSSL when administered in infant formula.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this double-blind crossover study, patients will be randomized to receive infant formula including BSSL or infant formula without BSSL for the first 7 days.
After a wash-out period of 2 days the patients will "crossover" to the other treatment regimen and receive an additional 7 days treatment.
The primary efficacy measurements will be made by collecting stool during the last three days of each treatment period.
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ancona, Italy
- Presidio Ospedaliero di Alta Specializzazione G.Salesi Azienda Ospedaliero Universitaria Ospedali Riuniti "Umberto I-G.M.Lancisi -G.Salesi
-
Bari, Italy
- Azienda Ospedaliera "Ospedale Policlinico Consorziale",U.O Neonatologia e Terapia Intensiva Neonatale
-
Milano, Italy
- 3) U.O. di Neonatologia e Terapia Intensiva Neonatale Università degli Studi di Milano, Ospedale Maggiore Policlinico,Mangiagalli e Regina Elena-Fondazione IRCCS
-
Padova, Italy
- 4) Policlinico Universitario-Azienda Ospedaliera di Padova, Dipartimento di Pediatria
-
Rome, Italy
- Clinical Pediatrica-Neonatologia, Policlinico Gemelli, Universita Cattolica
-
Rome, Italy
- U.O. Neonatologia, Patologia Neonatale e Terapia Intensiva
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 7 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Preterm infants
- less than or equal to 32 weeks of gestational age
- appropriate for gestational age
- enterally fed with infant formula
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
One week treatment
|
Active Comparator: rhBSSL
|
0.15 g/L rhBSSL added to infant formula; one week treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Coefficient of Fat Absorption in stool
Time Frame: Stool collected for a 72-hour period during the final 3 days of each treatment period
|
Stool collected for a 72-hour period during the final 3 days of each treatment period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in length and body weight between the start and end of each treatment period
Time Frame: Baseline and after one week of treatment
|
Baseline and after one week of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kristina Timdahl, MD, Biovitrum AB
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
April 14, 2008
First Submitted That Met QC Criteria
April 15, 2008
First Posted (Estimate)
April 16, 2008
Study Record Updates
Last Update Posted (Estimate)
November 2, 2014
Last Update Submitted That Met QC Criteria
October 31, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BVT.BSSL-020
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Replacement Therapy in Preterm Infants
-
Swedish Orphan BiovitrumCompletedReplacement Therapy in Preterm InfantsFrance, Italy
-
Mansoura University Children HospitalCompletedOxidative Stress in Preterm InfantsEgypt
-
Ankara City Hospital BilkentRecruitingCentral Nervous System Vulnerabilities in Preterm InfantsTurkey
-
Loma Linda UniversityCompletedAdjunctive Music Therapy in Total Knee ReplacementUnited States
-
Georgetown UniversityCompletedParental Infant Bonding | Cardio-respiratory Stability in Preterm NICU InfantsUnited States
-
Seoul National University HospitalRotaryCompletedNoninvasive Neurally Adjusted Ventilatory Assist and Pressure Support in Preterm InfantsKorea, Republic of
-
Hadassah Medical OrganizationWithdrawnPreterm Infants With White Matter Damage | Preterm Infants Developing Normally
-
Maquet Critical Care ABNAMSA; Paediatric and Neonatal Mechanical Ventilation (PNV) ConsultingNot yet recruitingElective HFOV for Respiratory Failure in Neonates/Infants | Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy
-
Zekai Tahir Burak Women's Health Research and Education...CompletedCompare of Effectiveness Cycled Light and Near Darkness on Growth in Preterm InfantsTurkey
-
Central Hospital, Nancy, FranceUnknownDiphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates (VacciPrema)Hib Immunisation in Very Preterm-born Infants | Pertussis Immunisation in Very Preterm-born InfantsFrance
Clinical Trials on rhBSSL
-
Swedish Orphan BiovitrumCompletedCystic Fibrosis | Exocrine Pancreatic InsufficiencyNetherlands, Poland
-
Swedish Orphan BiovitrumCompletedReplacement Therapy in Preterm InfantsFrance, Italy
-
Swedish Orphan BiovitrumTerminatedPrevention of Growth RestrictionBelgium, France, Germany, Hungary, Italy, Poland, Spain, Sweden, Czech Republic, Russian Federation